2/11
06:49 am
mdgl
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
Low
Report
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
2/11
06:31 am
mdgl
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
Low
Report
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
2/11
06:25 am
mdgl
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
Low
Report
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
2/11
05:00 am
mdgl
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
Low
Report
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
2/5
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
2/2
08:05 am
mdgl
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
Low
Report
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
1/29
07:41 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
1/27
06:00 pm
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
1/22
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
1/21
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
1/20
09:02 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Citizens Jmp from $527.00 to $745.00. They now have a "market outperform" rating on the stock.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Citizens Jmp from $527.00 to $745.00. They now have a "market outperform" rating on the stock.
1/20
07:01 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
1/14
07:36 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/14
03:01 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/12
09:08 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/10
01:24 pm
mdgl
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum [Yahoo! Finance]
Low
Report
Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility And Long Term Momentum [Yahoo! Finance]
1/10
03:36 am
mdgl
Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed [Yahoo! Finance]
1/9
08:00 am
mdgl
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
Medium
Report
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
1/6
07:28 pm
mdgl
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday [Yahoo! Finance]
Low
Report
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday [Yahoo! Finance]
1/6
09:02 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $579.00 price target on by analysts at Wolfe Research.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $579.00 price target on by analysts at Wolfe Research.
1/6
08:06 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was downgraded by analysts at Wolfe Research from an "outperform" rating to a "peer perform" rating.
1/5
05:23 pm
mdgl
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead [Yahoo! Finance]
Medium
Report
Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead [Yahoo! Finance]
1/5
11:22 am
mdgl
$18.67 Bn MASH Treatment Market Trends, Opportunities and Strategies, 2019-2024, 2025-2029 & 2034 [Yahoo! Finance]
Low
Report
$18.67 Bn MASH Treatment Market Trends, Opportunities and Strategies, 2019-2024, 2025-2029 & 2034 [Yahoo! Finance]
1/5
08:44 am
mdgl
Madrigal: Rezdiffra Shift To F4c MASH Cirrhosis Continues With 2-Year Data [Seeking Alpha]
Low
Report
Madrigal: Rezdiffra Shift To F4c MASH Cirrhosis Continues With 2-Year Data [Seeking Alpha]
1/3
04:25 am
mdgl
Madrigal Pharmaceuticals: My Take On Prospects For 2026 Leads To Rating Downgrade [Seeking Alpha]
Low
Report
Madrigal Pharmaceuticals: My Take On Prospects For 2026 Leads To Rating Downgrade [Seeking Alpha]